Related references
Note: Only part of the references are listed.Haemodiafiltration and mortality in end-stage kidney disease patients: a pooled individual participant data analysis from four randomized controlled trials
Sanne A. E. Peters et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2016)
Diagnostic Accuracy of Bone Turnover Markers and Bone Histology in Patients With CKD Treated by Dialysis
Stuart M. Sprague et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2016)
How Accurate is Your Sclerostin Measurement? Comparison Between Three Commercially Available Sclerostin ELISA Kits
Isabelle Piec et al.
CALCIFIED TISSUE INTERNATIONAL (2016)
Can we compare serum sclerostin results obtained with different assays in hemodialysis patients?
Rosa M. A. Moyses et al.
INTERNATIONAL UROLOGY AND NEPHROLOGY (2015)
A Randomized, Double-Blind Phase 2 Clinical Trial of Blosozumab, a Sclerostin Antibody, in Postmenopausal Women with Low Bone Mineral Density
Robert R. Recker et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2015)
Sclerostin Quo Vadis? - Is This a Useful Long-Term Mortality Parameter in Prevalent Hemodialysis Patients?
Albina Nowak et al.
KIDNEY & BLOOD PRESSURE RESEARCH (2015)
Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: potential partners in vascular calcifications
Marion Morena et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2015)
Serum sclerostin: the missing link in the bone-vessel cross-talk in hemodialysis patients?
S. Pelletier et al.
OSTEOPOROSIS INTERNATIONAL (2015)
High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study
Christiane Drechsler et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2015)
Survival Trends in ESRD Patients Compared With the General Population in the United States
Carl van Walraven et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2014)
Renal Elimination of Sclerostin Increases With Declining Kidney Function
Daniel Cejka et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Clinical and Biological Determinants of Sclerostin Plasma Concentration in Hemodialysis Patients
Pierre Delanaye et al.
NEPHRON CLINICAL PRACTICE (2014)
Fibroblast Growth Factor 23/Klotho Axis in Chronic Kidney Disease
Kosaku Nitta et al.
NEPHRON CLINICAL PRACTICE (2014)
Serum sclerostin is an independent predictor of mortality in hemodialysis patients
Flavia Leticia Carvalho Goncalves et al.
BMC NEPHROLOGY (2014)
Heart Failure in Patients with Chronic Kidney Disease: A Systematic Integrative Review
Liviu Segall et al.
BIOMED RESEARCH INTERNATIONAL (2014)
Bone: a new endocrine organ at the heart of chronic kidney disease and mineral and bone disorders
Marc G. Vervloet et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
The Relation between Renal Function and Serum Sclerostin in Adult Patients with CKD
Solenne Pelletier et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2013)
Sclerostin: Another Vascular Calcification Inhibitor?
Kathleen J. Claes et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
FGF-23 removal is improved by on-line high-efficiency hemodiafiltration compared to conventional high flux hemodialysis
Laure Patrier et al.
JOURNAL OF NEPHROLOGY (2013)
High-Efficiency Postdilution Online Hemodiafiltration Reduces All-Cause Mortality in Hemodialysis Patients
Francisco Maduell et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2013)
Mortality and cardiovascular events in online haemodiafiltration (OL-HDF) compared with high-flux dialysis: results from the Turkish OL-HDF Study
Ercan Ok et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2013)
Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis?
Liesbeth Viaene et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2013)
Sclerostin Levels Associated with Inhibition of the Wnt/β-Catenin Signaling and Reduced Bone Turnover in Type 2 Diabetes Mellitus
Agostino Gaudio et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Effect of Online Hemodiafiltration on All-Cause Mortality and Cardiovascular Outcomes
Muriel P. C. Grooteman et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2012)
Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients
Daniel Cejka et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2012)
Sclerostin and Dickkopf-1 in Renal Osteodystrophy
Daniel Cejka et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2011)
Short-term Effects of Online Hemodiafiltration on Phosphate Control: A Result From the Randomized Controlled Convective Transport Study (CONTRAST)
E. Lars Penne et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2010)
Sclerostin: Current Knowledge and Future Perspectives
M. J. C. Moester et al.
CALCIFIED TISSUE INTERNATIONAL (2010)
Sclerostin Mediates Bone Response to Mechanical Unloading Through Antagonizing Wnt/β-Catenin Signaling
Chuwen Lin et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Excess mortality due to interaction between protein-energy wasting, inflammation and cardiovascular disease in chronic dialysis patients
Renee de Mutsert et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2008)
International differences in dialysis mortality reflect background general population atherosclerotic cardiovascular mortality
Maki Yoshino et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
Effect of increased convective clearance by on-line hemodiafiltration on all cause and cardiovascular mortality in chronic hemodialysis patients -: the Dutch CONvective TRAnsport STudy (CONTRAST):: rationale and design of a randomised controlled trial [ISRCTN38365125] -: art. no. 8
EL Penne et al.
CURRENT CONTROLLED TRIALS IN CARDIOVASCULAR MEDICINE (2005)
Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States medicare population, 1998 to 1999
RN Foley et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2005)
Cardiovascular calcifications in uremic patients: Clinical impact on cardiovascular function
GM London
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2003)
Share Paper
